

# WFS1 E199G — Wolframin

Glutamic acid → Glycine at position 199. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.811, DynaMut2  $\Delta\Delta G$  -1.18 kcal/mol (destabilising).

## IDENTITY

|                   |                                   |
|-------------------|-----------------------------------|
| Variant           | E199G (p.Glutamic acid199Glycine) |
| DNA change        | c.596A>G                          |
| Gene · Protein    | WFS1 · Wolframin (890 aa)         |
| UniProt           | O76024 · WFS1_HUMAN               |
| ClinVar accession | VCV002631626                      |
| Amino acid change | Glutamic acid (E) → Glycine (G)   |

## STRUCTURAL CONTEXT

|                      |   |
|----------------------|---|
| AlphaFold model      | AF-O76024-F1, v6                                  |
| pLDDT at residue 199 | <b>80.75</b> HIGH CONFIDENCE                      |
| Domain               | N-terminal cytoplasmic (intrinsically disordered) |
| Position context     | N-terminal cytoplasmic (intrinsically disordered) |
| IDR flag             | No — pLDDT well above 50 threshold                |

Position 199 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is negatively charged (glutamate — carboxylate); the mutant is small/flexible (glycine — backbone flexibility, no sidechain). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.811**am\_class: **likely pathogenic** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **-1.18** kcal/molDestabilising · Job  
178092115425

PLDDT (ALPHAFOLD)

**80.75**

high confidence

## CLINICAL EVIDENCE

|                        |  |
|------------------------|--|
| ClinVar classification | UNCERTAIN SIGNIFICANCE   |
| Review status          | criteria provided, single submitter  |
| Last evaluated         | 2023/07/18 00:00   |
| Inheritance            | Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations. |
| WFS1 variant landscape | E199G is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)          |
|                        | <ul style="list-style-type: none"> <li>WFS1-related disorder</li> </ul>                    |

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G 2-4$  → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

### Category 3/4 — Most Druggable

$|\Delta\Delta G|=1.18 < 2$  kcal/mol (fold intact) + AlphaMissense 0.811 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframin's fold survives this substitution ( $|\Delta\Delta G|=1.18$  kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.811. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.